ArticleBMC cancer2019
Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Pseudomyogenic hemangioendothelioma with bone and soft tissue involvement with favorable response to pamidronate: a case report and systematic review of the literature.Archives of osteoporosis · 2022Pooled it
- Pseudomyogenic hemangioendothelioma (involving skin, bone and soft tissue): a case report with long-term follow-up and review of literature.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Review
- Pseudomyogenic Hemangioendothelioma of the Femur Treated by Intercalary Resection and Massive Allograft Reconstruction: A Case Report.Case reports in orthopedics · 2026Article
- Case Report: Three rare cases of pseudomyogenic hemangioendothelioma with atypical skeletal involvement.Frontiers in medicine · 2026Article
- Penile pseudomyogenic hemangioendothelioma: a rare case report with clinicopathologic features and multidisciplinary management.Frontiers in medicine · 2026Article
- Ultrasonographic and pathological findings of pseudomyogenic hemangioendothelioma.The Kaohsiung journal of medical sciences · 2024Article
- Beyond the rare: a case of pseudomyogenic hemangioendothelioma treated sequentially with everolimus, denosumab, and pazopanib.Einstein (Sao Paulo, Brazil) · 2024Article
- Pseudomyogenic hemangioendothelioma of bone with rareClinical case reports · 2021Article
- The clinicopathological spectrum of pseudomyogenic hemangioendothelioma: report of an additional series with review of the literature.Virchows Archiv : an international journal of pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomyogenic hemangioendothelioma (PMHE) is a rare endothelial neoplasm that involves the bones in only 14% of all cases. The optimal treatment strategy has not been established. We herein report a case of primary PMHE in which denosumab treatment showed activity in both imaging studies and the clinical outcome. CASE PRESENTATION: A 20-year-old woman presented with worsening pain in her left ankle. Imaging studies showed multifocal fluorodeoxyglucose (FDG)-avid [maximum standardized uptake value (SUVmax), 15.95] osteolytic lesions in the bones of her left lower extremity. While waiting for the definitive pathologic diagnosis of PMHE, denosumab, a human immunoglobulin G2 monoclonal antibody against RANKL, was initiated to treat progressive bone absorption after curettage of one of the lesions. Denosumab induced osteosclerosis around the lesions and pain relief and was discontinued 4 years after its initiation. Although all of the multifocal lesions remained, they all became less FDG-avid (SUVmax, 2.6), and the patient developed no signs of new lesions or distant metastasis.
conclusionDenosumab plays a certain role in prevention of bone destruction by PMHE through suppression of osteoclast-like giant cells and would be an excellent treatment for bone absorption by PMHE of bone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.